Manual
Description
Fatty acid-binding proteins (FABPs) are a class of cytoplasmic proteins that bind long chain fatty acids. FABPs are small intracellular proteins (~13-14 kDa) with a high degree of tissue specificity. They are abundantly present in various cell types and play an important role in the intracellular utilization of fatty acids, transport and metabolism. There are at least nine distinct types of FABP, each showing a specific pattern of tissue expression. Due to its small size, FABP leaks rapidly out of ischemically damaged necrotic cells leading to a rise in serum levels. Ischemically damaged tissues are characterized histologically by absence (or low presence) of FABP facilitating recognition of such areas.
Liver-type fatty acid binding protein (L-FABP, FABP1) is predominantly expressed in liver. The L-FABP protein is derived from the human FABP1 gene. L-FABP is a sensitive marker for cell damage of liver cells in vitro and in vivo. L-FABP is also a marker for rapid hepatocyte lysis in vitro (as for example in toxicology assays) and for detection of liver damage during and after transplantation.
Serum/plasma and urine of healthy individuals contains approximately 12 ng/ml and 16 ng/ml L-FABP, respectively.
Cross Reactivity
|
Potential cross reacting proteins detected in the human L-FABP ELISA.
|
|
Cross reactant
|
Reactivity
|
|
Human H-FABP
Human I-FABP
Mouse/Rat L-FABP
Swine L-FABP
|
Negative
Negative
Negative
Positive
|
Application
The human L-FABP ELISA has been developed for the quantitative measurement of natural and recombinant human L-FABP in cell culture medium, serum, plasma and urine. In serum or plasma samples human L-FABP can be measured accurately if serum or plasma samples are diluted at least 20 times. Most reliable results are obtained if EDTA plasma is used. In urine samples, L-FABP can be measured accurately is urine is diluted at least 5 times.
Features
- Minimum concentration which can be measured is 100 pg/ml human L-FABP.
- Measurable concentration range of 102-25,000 pg/ml.
- Working volume of 100 µl/well.
Typical standard curve
Principle
- The human L-FABP ELISA is a ready-to-use solid-phase enzyme-linked immunosorbent assay based on the sandwich principle with a working time of 3½ hours.
- The efficient format of 2 plates with twelve disposable 8-well strips allows free choice of batch size for the assay.
- Samples and standards are incubated in microtiter wells coated with antibodies recognizing human L-FABP.
- Biotinylated tracer antibody will bind to captured human L-FABP.
- Streptavidin-peroxidase conjugate will bind to the biotinylated tracer antibody.
- Streptavidin-peroxidase conjugate will react with the substrate, tetramethylbenzidine (TMB).
- The enzyme reaction is stopped by the addition of citric acid.
- The absorbance at 450 nm is measured with a spectrophotometer. A standard curve is obtained by plotting the absorbance (linear) versus the corresponding concentrations of the human L-FABP standards (log).
- The human L-FABP concentration of samples, which are run concurrently with the standards, can be determined from the standard curve.
Aliases
FABP1
Optional use
Cytotoxicity protocol
- Culture 100 µl of 1.105 HUH-7 cells per ml in 96-wells plate.
- T=0: Add 100 µl of 2x test chemicals to 96-wells plate.
- Incubate 37 °C, 5% CO2.
- T=24: measure L-FABP in supernatant.
-
Storage and stability
Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least six months. After reconstitution the reagents are stable for 1 month if stored at 2-8°C.
Recovery
Normal human blood samples (plasma), containing baseline levels of human L-FABP, were spiked with human L-FABP] in concentrations of 0.2 and 5 ng/ml. Samples with and without L-FABP were incubated for 1 hour at room temperature. Samples were measured using the ELISA. Values for L-FABP ranged between 86% and 102% (mean 94%).
References
- Pelsers, M et al; Liver fatty acid-binding protein as a sensitive serum marker of acute hepatocellular damage in liver transplant recipients. Clin Chem 2002, 48: 2055
- Morariu, A et al; Dexamethasone: benefit and prejudice for patients undergoing on-pump coronary artery bypass grafting: a study on myocardial, pulmonary, renal, intestinal, and hepatic injury. Chest 2005, 128: 2677
- Pelsers, M et al; Fatty acid-binding proteins as plasma markers of tissue injury. Clinica Chimica Acta 2005 352: 15
Precautions
For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.
Also available